Halozyme Therapeutics, Inc. $HALO Holdings Increased by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. lifted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 66.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 52,500 shares of the biopharmaceutical company’s stock after buying an additional 21,000 shares during the quarter. Halozyme Therapeutics makes up 0.9% of Hussman Strategic Advisors Inc.’s holdings, making the stock its 10th largest position. Hussman Strategic Advisors Inc.’s holdings in Halozyme Therapeutics were worth $3,533,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the stock. Artemis Investment Management LLP boosted its stake in shares of Halozyme Therapeutics by 14.6% in the fourth quarter. Artemis Investment Management LLP now owns 114,596 shares of the biopharmaceutical company’s stock worth $7,712,000 after buying an additional 14,638 shares during the last quarter. Sigma Planning Corp boosted its stake in shares of Halozyme Therapeutics by 22.2% in the fourth quarter. Sigma Planning Corp now owns 9,592 shares of the biopharmaceutical company’s stock worth $646,000 after buying an additional 1,741 shares during the last quarter. New York State Teachers Retirement System boosted its stake in shares of Halozyme Therapeutics by 0.7% in the fourth quarter. New York State Teachers Retirement System now owns 125,968 shares of the biopharmaceutical company’s stock worth $8,478,000 after buying an additional 853 shares during the last quarter. Verity Asset Management Inc. boosted its stake in shares of Halozyme Therapeutics by 11.6% in the fourth quarter. Verity Asset Management Inc. now owns 53,118 shares of the biopharmaceutical company’s stock worth $3,575,000 after buying an additional 5,506 shares during the last quarter. Finally, Cardinal Capital Management boosted its stake in shares of Halozyme Therapeutics by 5.2% in the fourth quarter. Cardinal Capital Management now owns 18,689 shares of the biopharmaceutical company’s stock worth $1,258,000 after buying an additional 921 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total transaction of $1,284,800.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $49,322,187.20. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 20,000 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $67.80, for a total value of $1,356,000.00. Following the transaction, the chief operating officer directly owned 14,366 shares of the company’s stock, valued at $974,014.80. The trade was a 58.20% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 118,857 shares of company stock valued at $8,279,587 in the last three months. Insiders own 2.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on HALO. Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday, February 24th. HC Wainwright increased their price target on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday. Wall Street Zen downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. Wells Fargo & Company increased their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Finally, Benchmark increased their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $79.11.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $63.96 on Friday. The company has a market capitalization of $7.58 billion, a P/E ratio of 25.69, a P/E/G ratio of 0.26 and a beta of 0.89. The business’s 50 day moving average is $66.15 and its two-hundred day moving average is $68.59. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. Halozyme Therapeutics, Inc. has a 12-month low of $47.50 and a 12-month high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The business had revenue of $451.77 million for the quarter, compared to analysts’ expectations of $446.13 million. During the same quarter in the prior year, the company posted $1.26 EPS. The business’s revenue for the quarter was up 51.6% compared to the same quarter last year. Analysts expect that Halozyme Therapeutics, Inc. will post 7.68 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.